Company profile for Tiziana Life Sciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Tiziana Life Sciences is a dual-listed (NASDAQ:TLSA, AIM:TILS) clinical stage biotechnology company that specializes in the developing transformative therapies for inflammatory diseases and cancer related to the liver. Our clinical pipeline includes drug assets for NASH, Crohn's, and hepatocellular carcinoma. Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experienc...
Tiziana Life Sciences is a dual-listed (NASDAQ:TLSA, AIM:TILS) clinical stage biotechnology company that specializes in the developing transformative therapies for inflammatory diseases and cancer related to the liver. Our clinical pipeline includes drug assets for NASH, Crohn's, and hepatocellular carcinoma. Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experience. Our mission is to bring breakthrough therapies to patients with the aim of reversing severe liver diseases and optimizing health outcomes.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
55 Park Lane London W1K 1NA
Telephone
Telephone
+44 (0) 207 495 2379
Linkedin
Linkedin
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/02/3197761/0/en/Tiziana-Life-Sciences-Plans-to-Spinout-IL-6-Asset-into-Separate-Listed-Company.html

GLOBENEWSWIRE
02 Dec 2025

https://www.globenewswire.com/news-release/2025/11/25/3194320/0/en/Tiziana-Life-Sciences-Nasal-Foralumab-Phase-2-Clinical-Trial-Accepted-into-Healey-ALS-MyMatch-Program.html

GLOBENEWSWIRE
25 Nov 2025

https://www.pharmiweb.com/press-release/2025-11-13/tiziana-life-sciences-to-present-at-jefferies-global-healthcare-conference

PHARMIWEB
13 Nov 2025

https://www.globenewswire.com/news-release/2025/10/29/3176278/0/en/Tiziana-Life-Sciences-to-Present-at-BIO-Europe-in-Vienna-Highlighting-Innovative-Immunomodulation-Therapy.html

GLOBENEWSWIRE
29 Oct 2025

https://www.pharmiweb.com/press-release/2025-10-01/tiziana-life-sciences-invited-to-attend-life-sciences-innovation-forum-2025-in-riyadh-saudi-arabia

PHARMIWEB
01 Oct 2025

https://www.globenewswire.com/news-release/2025/09/30/3158596/0/en/Tiziana-Life-Sciences-Invited-to-Attend-Life-Sciences-Innovation-Forum-2025-in-Riyadh-Saudi-Arabia.html

GLOBENEWSWIRE
30 Sep 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Contact Tiziana Life Sciences and get a quotation

Tiziana Life Sciences is a supplier offers 1 products (APIs, Excipients or Intermediates).

Find a price of FORALUMAB ORAL bulk offered by Tiziana Life Sciences

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty